Why the study?
Does inclacumab reduce myocardial damage after PCI in patients with non-ST-segment elevation myocardial infarction?
Does inclacumab reduce myocardial damage after PCI in patients with non-ST-segment elevation myocardial infarction?
Inclacumab may reduce myocardial damage following percutaneous coronary intervention in patients with NSTEMI.
No takes yet. Share an insight, caveat, or question.
May support inclacumab as adjunctive therapy to limit periprocedural injury in NSTEMI; extends targeted anti-inflammatory approaches in ACS.
Tardif et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: